Cite
HARVARD Citation
Overton, E. et al. (2020). Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 396 (10267), pp. 1994-2005. [Online].